Supplementary Table 1. Response rates in the overall population according to baseline HBeAb and prior NA therapy at week 48 of Peg-IFN alfa-2a treatment

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | HBsAg loss, (%) | *P* | HBsAg seroconversion, (%) | *P* |
| Baseline HBeAb | |  |  |  |
| Negative, *n*=130 | 15 (11.5) | 0.4969 | 12 (9.2) | 0.3641 |
| Positive, *n*=173 | 25 (14.5) | 23 (13.3) |
| Prior NA therapy | |  |  |  |
| LAM, *n*=84 | 8 (9.5) | LAM vs. ETV 0.3845  LAM vs. ADV 0.2774  ETV vs. ADV 0.8496 | 7 (8.3) | LAM vs. ETV 0.6343  LAM vs. ADV 0.2564  ETV vs. ADV 0.5496 |
| ETV, *n*=114 | 16 (14.0) | 13 (11.4) |
| ADV, *n*=105 | 16 (15.2) | 15 (14.3) |

### Abbreviations: ADV, adefovir; ETV, entecavir; HBsAg, hepatitis B surface antigen; LAM, lamivudine; NA, nucleos(t)ide analogue; Peg-IFN, pegylated-interferon.

Supplementary Table 2. Baseline clinical characteristics of 12 patients with HBsAg relapse between end of treatment and end of follow-up

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | 48-week Peg-IFN alfa-2a, =4 | | | | 96-week PegIFN alfa-2a, =8 | | | | | | | |
| Sex | M | F | F | M | M | M | M | M | F | M | M | F |
| Age in years | 37 | 47 | 22 | 23 | 35 | 40 | 31 | 20 | 35 | 29 | 40 | 19 |
| Weight in kg | 60.0 | 56.3 | 41.5 | 45.0 | 73.0 | 65.0 | 72.0 | 53.0 | 47.7 | 55.0 | 65.5 | 55.0 |
| Duration of diagnosed HBV infection in years | 10 | 15 | 2 | 9 | 13 | 3 | 4 | 3 | 8 | 5 | 3 | 4 |
| Prior NA treatment |  |  |  |  |  |  |  |  |  |  |  |  |
| Lamivudine |  |  |  |  |  |  |  | Y | Y |  |  |  |
| Entecavir | Y |  |  |  |  | Y |  |  |  | Y |  |  |
| Adefovir |  | Y | Y | Y | Y |  | Y |  |  |  | Y | Y |
| Duration of prior NA treatment in years | 1.67 | 1.08 | 1 | 1.5 | 2.5 | 1.58 | 2.25 | 2.17 | 1.92 | 1.75 | 1.58 | 1.17 |
| HBsAg in IU/mL | 9.61 | 922.3 | 1306 | 2280 | 36.4 | 724.8 | 538 | 257.8 | 364 | 5356 | 181.5 | 1151 |
| HBeAg seroconversion | Yes | Yes | No | Yes | Yes | No | Yes | No | Yes | Yes | Yes | No |
| HBV DNA as log10 IU/mL | <20 | TND | <200 | <20 | <20 | <20 | TND | <20 | TND | TND | <20 | <20 |
| APRI score | <0.5 | <0.5 | <0.5 | <0.5 | <0.5 | <0.5 | <0.5 | <0.5 | <0.5 | <0.5 | <0.5 | <0.5 |
| ALT in IU/mL | 19.0 | 23.0 | 18.0 | 16.0 | 26.0 | 15.3 | 30.0 | 22.4 | 14.0 | 16.0 | 23.0 | 8.0 |

Abbreviations: APRI, aspartate aminotransferase-to-platelet ratio index; F, Female; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; Peg-IFN, pegylated-interferon; M, Male; NA, nucleos(t)ide analogue; TND, target not detected; Y, yes.

Supplementary Table 3. HBsAg loss rates after 48 weeks of PegIFN alfa-2a treatment in the overall population according to on-treatment HBsAg levels

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Baseline HBsAg in IU/mL, N=303** | ***n*/N (%)** | **Week 12 HBsAg in IU/mL, *n*=295\*** | ***n*/N (%)** | **Week 24 HBsAg in IU/mL, *n*=284†** | ***n*/N (%)** | **Week 48 HBsAg loss, *n*/N (%)** |
| <1500 | 138/303 (45.5) | <500 | 82/138 (59.4) | <200 | 67/82 (81.7) | 32/67 (47.8) |
| ≥200 | 11/82 (13.4) | 0 |
| ≥500 | 52/138 (37.7) | <200 | 14/52 (26.9) | 3/14 (21.4) |
| ≥200 | 34/52 (65.4) | 0 |
| ≥1500 | 165/303 (54.5) | <500 | 12/165 (7.3) | <200 | 10/12 (83.3) | 2/10 (2) |
| ≥200 | 2/12 (16.7) | 0 |
| ≥500 | 149/165 (90.3) | <200 | 8/149 (5.4) | 3/8 (37.5) |
| ≥200 | 138/149 (92.6) | 0 |

\*8 patients had missing data at week 12; †19 patients had missing data at week 24.

Abbreviations: HBsAg, hepatitis B surface antigen; Peg-IFN, pegylated-interferon.